Form 4 for PALI PALISADE BIO, INC.
Accepted 2023-11-24 00:00:00 ET · period of report 2023-11-20 · accession 0001493152-23-042663 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-24 | 2023-11-20 | PALI | Finley John David | CEO, CFO, Dir | A - Grant | $0.51 | +10.0K | 57.8K | +21% | +$5,100 |
| DM | 2023-11-24 | 2023-11-21 | PALI | Finley John David | CEO, CFO, Dir | A - Grant | $0.00 | +83.0K | 45.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.01 | 2023-11-20 | A | A | 10,000 | $0.51 | 57,781 | D | — | — | (F1) Shares were purchased pursuant to the Palisade Bio, Inc. 2021 Employee Stock Purchase Plan, as amended ("ESPP") for the ESPP purchase period from July 1, 2023 through November 20, 2023. In accordance with the ESPP, the shares were purchased in a transaction exempt under Rule 16b-3(c) at a price equal to 85% of the closing price of the issuer's common stock on November 20, 2023. |
| 2 | Derivative | Restricted Stock Units | 2023-11-21 | A | A | 38,000 | $0.00 | 38,000 | D | — · — to — | 38,000 Common Stock | (F5) The grant vests in twelve (12) equal quarterly installments over a three (3) year period with the first vesting date to occur on February 6, 2024. (F4) Each restricted stock unit represents the right to receive, at settlement, one share of common stock. (F3) The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. (F6) N/A. |
| 3 | Derivative | Common Stock Options | 2023-11-21 | A | A | 45,000 | $0.00 | 45,000 | D | $0.59 · — to 2033-11-21 | 45,000 Common Stock | (F8) The grant vests in twelve (12) equal quarterly installments over a three (3) year period from the grant date. (F7) Each option represents the right to purchase one share of common stock at the exercise price. (F3) The Grants were made as discretionary grants to Reporting Person from the Issuer's 2021 Equity Incentive Plan, as amended ("Plan"). Pursuant to Nasdaq rules, no shares may be issued pursuant to the grants until such time as there are sufficient shares of common stock available under the Plan. The applicable vesting for each grant is subject to the Reporting Person continuing to be a service provider to Issuer at the time of vesting. |